{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:45:03Z","timestamp":1785800703391,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NHS Specialised Commissioning"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiorenal metabolic (CRM) disease, is identified by the co-location of multiple disorders including obesity, diabetes, hypertension, cardiovascular disease and chronic kidney disease (CKD). Early intervention is essential to slow CKD progression, reduce cardiovascular risk, and improve quality of life. The Harrow CRM Hub project established a personalised, multidisciplinary pathway to identify high-risk patients, optimise clinical management, and provide access to lifestyle and psychosocial support. This paper reports on the clinical outcomes achieved within the first year of implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive logic model was co-developed to guide the design, delivery, and evaluation of the Harrow CRM programme. Two EHR-identified cohorts were invited: (1) adults aged 20\u201380 years with BMI &gt;27.5\u201330 kg\/m\u00b2 (ethnicity-dependent) and non-diabetic hyperglycaemia \u00b1 hypertension (CRM Stage 2); and (2) adults with diabetes \u00b1 CKD or CVD (CRM Stage 4). Pre visit health questionnaire \u2013 using digital tools enabled detailed pre visit updates and tests. Protected consultations (lasting 30 to 45 minutes) followed a structured EHR template incorporating guideline-based optimisation of pharmacotherapy, risk calculators, and co-created lifestyle care plans. Data were extracted for paired analysis of systolic BP, HbA1c, and weight. A qualitative evaluation was undertaken to explore patient and staff experiences of the CRM pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thus far, between November 2024 and September 2025, 2,641 patients were reviewed, with 2,300 included in paired analysis. Across the full cohort, mean changes were \u22123.65 mmHg in systolic BP (median \u22122.0 mmHg), \u22121.03 mmol\/mol in HbA1c (median 0.0 mmol\/mol), and \u22120.46 kg in weight (median 0.0 kg) (all p&lt;0.001). For those with an improvement only - an average improvement of \u221214.12 mmHg (n=1,279) and an average deterioration of +10.61 mmHg among those whose readings worsened (n=895). HbA1c values showed a mean cohort wide reduction of \u22121.03 mmol\/mol (median 0.0 mmol\/mol), with mean changes of \u22128.08 mmol\/mol among improvers (n=785) and +5.22 mmol\/mol among those with deterioration (n=762). Weight trends showed a mean overall reduction of \u22120.46 kg (median 0.0 kg), comprising an average improvement of \u22123.63 kg among improvers (n=1,124) and deterioration of +3.93 kg among those with deterioration (n=761). Among those with paired readings, 33.4% achieved \u22655% BP reduction and 19.7% achieved \u226510%; 19.8% achieved \u22655% HbA1c improvement and 12.7% \u226510%; and 9.6% achieved \u22655% weight loss and 2.7% \u226510%. Overall, 73.9% improved in \u22651 parameter, while 10.4% improved across BP, HbA1c, and weight simultaneously. This real world review identified patients with improvements and deterioration in their health parameters. Qualitative findings showed patients valued extended consultations and holistic discussions, with vast majority of patients reporting greater understanding of their health and feeling more confident to manage it. A staff survey (n=14) provided supportive but preliminary quantitative evidence of having greater confidence in delivering CRM clinics and increased ability to access multidisciplinary expertise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A personalised, multidisciplinary CRM model embedded within primary care was associated with statistically and clinically significant improvements in blood pressure, glycaemic control, and weight in a large, ethnically diverse population. Patients and clinicians both reported greater engagement, confidence, and satisfaction. The approach combining structured identification, extended consultations, co-produced care plans, and workforce education demonstrates a scalable, sustainable pathway to slow CKD progression, reduce CVD risk, and enhance patient wellbeing across diverse communities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05040-7","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:14:56Z","timestamp":1780060496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world preventive primary care model for cardiorenal metabolic disease: clinical impact of a personalised care approach in Harrow, North West London"],"prefix":"10.1186","volume":"27","author":[{"given":"R.","family":"Dattani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siddik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Brookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kelshiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Johal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"5040_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22(1):195. https:\/\/doi.org\/10.1186\/s12933-023-01937-x. PMID: 37525273; PMCID: PMC10391899.","journal-title":"Cardiovasc Diabetol"},{"key":"5040_CR2","doi-asserted-by":"publisher","first-page":"1526482","DOI":"10.3389\/fendo.2025.1526482","volume":"16","author":"K Xie","year":"2025","unstructured":"Xie K, Cao H, Ling S, Zhong J, Chen H, Chen P, Huang R. Global, regional, and national burden of chronic kidney disease, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Front Endocrinol (Lausanne). 2025;16:1526482. PMID: 40110544; PMCID: PMC11919670.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5040_CR3","unstructured":"Public Health England. Chronic kidney disease prevalence model \u2013 2021 update. London: PHE. 2021.Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5a82c379e5274a2e8ab593af\/ChronickidneydiseaseCKDprevalencemodelbriefing.pdf. Accessed 1\/10\/2025."},{"key":"5040_CR4","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism. 2024;160:155999. https:\/\/doi.org\/10.1016\/j.metabol.2024.155999. Epub 2024 Aug 14. PMID: 39151887.","journal-title":"Metabolism"},{"key":"5040_CR5","doi-asserted-by":"publisher","unstructured":"Berrington de Gonzalez A, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363(23):2211-9. https:\/\/doi.org\/10.1056\/NEJMoa1000367. Erratum in: N Engl J Med. 2011;365(9):869. PMID: 21121834; PMCID: PMC3066051.","DOI":"10.1056\/NEJMoa1000367"},{"key":"5040_CR6","doi-asserted-by":"publisher","unstructured":"Rao Kondapally Seshasai S, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa1008862. Erratum in: N Engl J Med. 2011;364(13):1281. PMID: 21366474; PMCID: PMC4109980.","DOI":"10.1056\/NEJMoa1008862"},{"key":"5040_CR7","doi-asserted-by":"publisher","unstructured":"Gansevoort RT, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352. https:\/\/doi.org\/10.1016\/S0140-67361360595-4. Epub 2013 May 31. PMID: 23727170.","DOI":"10.1016\/S0140-67361360595-4"},{"key":"5040_CR8","unstructured":"Public Health England. Health matters: combating high blood pressure. London: Public Health England. 2017. Available from: https:\/\/www.gov.uk\/government\/publications\/health-matters-combating-high-blood-pressure."},{"key":"5040_CR9","unstructured":"NHS England (London Region). Diabetes: understanding the challenge in London. London: NHS England. 2015. Available from: https:\/\/www.england.nhs.uk\/london\/wp-content\/uploads\/sites\/8\/2019\/07\/dia-understanding-ldn-challenges-022015.pdf."},{"key":"5040_CR10","unstructured":"Public Health England. Chronic kidney disease prevalence and cost model \u2013 2021 update. London: Public Health England. 2021. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2022-part-2\/kidney-disease#undiagnosed-ckd."},{"issue":"5S","key":"5040_CR11","first-page":"S1","volume":"102","author":"KDIGO Diabetes Work Group","year":"2022","unstructured":"KDIGO Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1\u2013127.","journal-title":"Kidney Int"},{"key":"5040_CR12","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025 Jan 1;48(Suppl 1):S27-S49 https:\/\/doi.org\/10.2337\/dc25-S002. PMID: 39651986; PMCID: PMC11635041.","DOI":"10.2337\/dc25-S002"},{"key":"5040_CR13","doi-asserted-by":"publisher","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific document group. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192. Erratum in: Eur Heart J. 2023 Dec 21;44(48):5060. https:\/\/doi.org\/10.1093\/eurheartj\/ehad774. Erratum in: Eur Heart J. 2024 Feb 16;45(7):518. https:\/\/doi.org\/10.1093\/eurheartj\/ehad857. PMID: 37622663.","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"5040_CR14","doi-asserted-by":"publisher","first-page":"1583702","DOI":"10.3389\/fcvm.2025.1583702","volume":"12","author":"M Iacoviello","year":"2025","unstructured":"Iacoviello M, Gori M, Grandaliano G, Minutolo R, Pitocco D, Trevisan R. A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective. Front Cardiovasc Med. 2025;12:1583702. https:\/\/doi.org\/10.3389\/fcvm.2025.1583702. PMID: 40264513; PMCID: PMC12011791.","journal-title":"Front Cardiovasc Med"},{"key":"5040_CR15","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203). London: NICE. 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/ng203."},{"key":"5040_CR16","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). London: NICE; updated 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ng28."},{"key":"5040_CR17","unstructured":"National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181). London: NICE; updated 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/cg181."},{"key":"5040_CR18","unstructured":"The King\u2019s Fund. Improving clinical co-ordination of care for people with multiple long-term conditions: the art of the possible. London: The King\u2019s Fund. 2022. Available from: https:\/\/www.kingsfund.org.uk\/publications\/improving-clinical-co-ordination-care-multiple-long-term-conditions."},{"key":"5040_CR19","doi-asserted-by":"publisher","unstructured":"Ortiz A, Arreola Guerra JM, Chan JCN, Jha V, Kramer H, Nicholas SB, Pavkov ME, Wanner C, Wong LP, Cheung M, King JM, Grams ME, Jadoul M, Tuttle KR, Conference Participants. Preventing chronic kidney disease and maintaining kidney health: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2025;108(4):555\u2013571. https:\/\/doi.org\/10.1016\/j.kint.2025.04.005. Epub 2025 Jun 19. PMID: 40536455.","DOI":"10.1016\/j.kint.2025.04.005"},{"key":"5040_CR20","unstructured":"Gpcontract.co.uk. QOF Database: NHS England [Internet]. 2025 [accessed 12\/11\/2025]. Available from: https:\/\/www.gpcontract.co.uk\/."},{"issue":"3","key":"5040_CR21","doi-asserted-by":"publisher","first-page":"CD010523","DOI":"10.1002\/14651858.CD010523.pub2","volume":"2015","author":"A Coulter","year":"2015","unstructured":"Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev. 2015;2015(3):CD010523. https:\/\/doi.org\/10.1002\/14651858.CD010523.pub2. PMID: 25733495; PMCID: PMC6486144.","journal-title":"Cochrane Database Syst Rev"},{"key":"5040_CR22","unstructured":"NHS England. Personalised care: health coaching and peer support framework. London: NHS England. 2020. Available from: https:\/\/www.england.nhs.uk\/personalisedcare\/health-coaching\/."},{"key":"5040_CR23","unstructured":"NHS England. The NHS long term plan. London: NHS England. 2019. Available from: https:\/\/www.longtermplan.nhs.uk\/."},{"key":"5040_CR24","unstructured":"England NHS. Core20PLUS5: an approach to reducing healthcare inequalities. London: NHS England; 2022. Available from: https:\/\/www.england.nhs.uk\/about\/equality\/equality-hub\/core20plus5\/."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05040-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05040-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05040-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:03:20Z","timestamp":1785798200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05040-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5040"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05040-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was conducted as a NHS-commissioned service evaluation \/ quality improvement project within the NHS. It does therefore not require NHS REC approval as per the NHS Health Authority (HRA) decision tool available from:\n                      \n                      . This study was conducted as a service evaluation \/ quality improvement project. In accordance with the UK Health Research Authority (HRA) decision tool, it did not require NHS Research Ethics Committee approval. All methods were performed in accordance with relevant guidelines and regulations, including the principles outlined in the Declaration of Helsinki. Participants were contacted by telephone and informed about the purpose of the evaluation. Attendance at the session was taken as implied consent to participate, and all individuals were free to decline without any impact on their routine care.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RD has received research project grants from the Institute of Global Health Innovation and has consultancy agreements with Discover Now and Boehringer Ingelheim. AHF has been in receipt of research grants, prepared educational materials, and attended drug advisory boards for Boehringer Ingelheim, Eli Lilly, AstraZeneca Limited, NAPP, VP UK, Bayer and GSK. MJ is supported by a CardioRenal Metabolic disease fellowship funded by NWL ICB. All other authors do not have any competing interest to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"450"}}